linsitinib
Sign in to saveAlso known as OSI-9606
Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- neoplasm, small cell lung carcinoma, hepatocellular carcinoma, prostate adenocarcinoma
via ChEMBL · EBI
Wikidata facts
- Mass
- 421.19026035599995
Show 4 more facts
- isomeric SMILES
- C[C@]1(C[C@@H](C1)C=2N3C(C(=NC=C3)N)=C(N2)C4=CC5=NC(=CC=C5C=C4)C6=CC=CC=C6)O
- canonical SMILES
- CC1(CC(C1)C=2N3C(C(=NC=C3)N)=C(N2)C4=CC5=NC(=CC=C5C=C4)C6=CC=CC=C6)O
- chemical formula
- C₂₆H₂₃N₅O
- Commons category
- Linsitinib
via Wikidata · CC0
~1 min read
Article
2 sectionsContents
- References
- External links
Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis.
Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012.